Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, in Parallel Groups Comparative Study of Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Omalizumab (JSC "GENERIUM", Russia) and Xolair® ("Novartis Pharma AG", Switzerland) After Single-dose Subcutaneous Administration in Healthy Volunteers at 150 mg

NCT04601389 is registered in ClinicalTrials.gov with AO GENERIUM as lead sponsor.

NCT NCT04601389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04601389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, in Parallel Groups Comparative Study of Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Omalizumab (JSC "GENERIUM", Russia) and Xolair® ("Novartis Pharma AG", Switzerland) After Single-dose Subcutaneous Administration in Healthy Volunteers at 150 mg
Lead sponsor
AO GENERIUM
Phase
Phase 1
Overall status
Completed
Start date
April 18, 2017
Completion date
September 6, 2017
Enrollment
84 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers